- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Metformin and life-style modifications fail to prevent Cardiovascular events in long run
In a new study conducted by Ronald B. Goldberg and colleagues, it was shown that despite long-term diabetes prevention, neither metformin nor lifestyle modifications prevented major cardiovascular events in the Diabetes Prevention Program Outcomes Study (DPPOS) after 21 years.
The findings of this study were published in Circulation.
Although lifestyle interventions and metformin have been found to prevent diabetes, their efficiency in avoiding cardiovascular disease linked with diabetes development remains unknown. As a result, the purpose of this investigation was to see if these therapies lowered the incidence of major cardiovascular events among participants in the Diabetes Prevention Program trial and Diabetes Prevention Program Outcomes Study over a 21-year median follow-up period.
During the DPP, 3234 patients with weakened glucose tolerance were randomly allocated to metformin 850 mg twice daily, an intensive lifestyle intervention, or a placebo and were monitored for three years. During the subsequent 18-year average follow-up in DPPOS, all patients were provided a less rigorous group lifestyle intervention, and the metformin group continued to receive unmasked metformin. The primary outcome was the first stroke, nonfatal myocardial infarction, or cardiovascular mortality determined by conventional criteria. The primary result or hospitalization for heart failure or unstable angina, coronary heart disease, coronary or peripheral revascularization, identified by angiography, or silent myocardial infarction by ECG were all considered prolonged cardiovascular outcomes. ECGs and cardiovascular risk variables were assessed on a yearly basis.
The key findings of this study were as follow:
1. Metformin and lifestyle interventions had no effect on the primary outcome: metformin versus placebo hazard ratio was 1.03 and lifestyle versus placebo hazard ratio was 1.14, respectively.
2. These results were unaffected by risk factor adjustment.
3. There was no effect of either strategy on the long-term cardiovascular prognosis.
In conclusion, neither metformin nor lifestyle prevented major cardiovascular events in DPPOS after 21 years even after long-term diabetes prevention. The provision of a group lifestyle intervention to all participants, widespread out-of-study use of statins and antihypertensive medications, and a decline in study metformin use combined with out-of-study metformin use across time may have diluted the treatments' benefits.
Reference:
Goldberg, R. B., Orchard, T. J., Crandall, J. P., Boyko, E. J., Budoff, M., Dabelea, D., Gadde, K. M., Knowler, W. C., Lee, C. G., Nathan, D. M., Watson, K., & Temprosa, M. (2022). Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study. In Circulation. Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.1161/circulationaha.121.056756
Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751